Journal scan

Anti-tau vaccine is successful in clinical trial for people with Alzheimer’s disease

Available drugs treat the symptoms of Alzheimer's disease, but do not halt or slow disease progression. There is an urgent need for disease-modifying drugs.

Alzheimer’s disease progressively impairs cognition and daily function and death usually occurs five to ten years after diagnosis. Available drugs treat the symptoms of the disease, but do not halt or slow disease progression. There is an urgent need for disease-modifying drugs

People who have Alzheimer’s disease have amyloid plaques between the neurones in the brain and tau protein tangles in the neurones. Research on development of disease-modifying drugs has mainly focused on amyloid plaques but this has not led to any new marketable treatments. As a result, the search for treatment is now looking at different avenues and tau pathology is regarded as one of the most promising targets.

Correlation

Several studies have shown that the amount of tau pathology in the brain is strongly correlated with the progression of Alzheimer’s disease.

...

Want to read more?

Unlock full access to RCNi Plus today

Save over 50% on your first three months:

  • Customisable clinical dashboard featuring 200+ topics
  • Unlimited online access to all 10 RCNi Journals including Nursing Older People
  • RCNi Learning featuring 180+ RCN accredited learning modules
  • NMC-compliant RCNi Portfolio to build evidence for revalidation
  • Personalised newsletters tailored to your interests

This article is not available as part of an institutional subscription. Why is this?

Jobs